Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Change in Inventory (2022 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Change in Inventory for 4 consecutive years, with -$170000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Change in Inventory rose 65.31% to -$170000.0 in Q1 2025 year-over-year; TTM through Sep 2025 was -$328000.0, a 125.89% decrease, with the full-year FY2024 number at -$1.1 million, down 134.18% from a year prior.
  • Change in Inventory was -$170000.0 for Q1 2025 at Whitehawk Therapeutics, down from -$158000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $2.2 million in Q4 2023 to a low of -$630000.0 in Q3 2024.
  • A 4-year average of $295384.6 and a median of $7000.0 in 2022 define the central range for Change in Inventory.
  • Biggest YoY gain for Change in Inventory was 861.39% in 2023; the steepest drop was 4700.0% in 2023.
  • Whitehawk Therapeutics' Change in Inventory stood at $1.1 million in 2022, then soared by 97.43% to $2.2 million in 2023, then plummeted by 107.1% to -$158000.0 in 2024, then decreased by 7.59% to -$170000.0 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Change in Inventory are -$170000.0 (Q1 2025), -$158000.0 (Q4 2024), and -$630000.0 (Q3 2024).